Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP692080.RAGm54tZjKdrgO9yl8IoXH58vdJwlmD5k_BrYjBCFqtjU130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP692080.RAGm54tZjKdrgO9yl8IoXH58vdJwlmD5k_BrYjBCFqtjU130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP692080.RAGm54tZjKdrgO9yl8IoXH58vdJwlmD5k_BrYjBCFqtjU130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP692080.RAGm54tZjKdrgO9yl8IoXH58vdJwlmD5k_BrYjBCFqtjU130_provenance.
- NP692080.RAGm54tZjKdrgO9yl8IoXH58vdJwlmD5k_BrYjBCFqtjU130_assertion description "[The human epidermal growth factor receptor-2 (HER2) is overexpressed and/or amplified in up to 25% of breast cancer patients, and this feature is associated with an aggressive phenotype, high recurrence rate and reduced survival.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP692080.RAGm54tZjKdrgO9yl8IoXH58vdJwlmD5k_BrYjBCFqtjU130_provenance.
- NP692080.RAGm54tZjKdrgO9yl8IoXH58vdJwlmD5k_BrYjBCFqtjU130_assertion evidence source_evidence_literature NP692080.RAGm54tZjKdrgO9yl8IoXH58vdJwlmD5k_BrYjBCFqtjU130_provenance.
- NP692080.RAGm54tZjKdrgO9yl8IoXH58vdJwlmD5k_BrYjBCFqtjU130_assertion SIO_000772 18779850 NP692080.RAGm54tZjKdrgO9yl8IoXH58vdJwlmD5k_BrYjBCFqtjU130_provenance.
- NP692080.RAGm54tZjKdrgO9yl8IoXH58vdJwlmD5k_BrYjBCFqtjU130_assertion wasDerivedFrom befree-2016 NP692080.RAGm54tZjKdrgO9yl8IoXH58vdJwlmD5k_BrYjBCFqtjU130_provenance.
- NP692080.RAGm54tZjKdrgO9yl8IoXH58vdJwlmD5k_BrYjBCFqtjU130_assertion wasGeneratedBy ECO_0000203 NP692080.RAGm54tZjKdrgO9yl8IoXH58vdJwlmD5k_BrYjBCFqtjU130_provenance.
- befree-2016 importedOn "2016-02-19" NP692080.RAGm54tZjKdrgO9yl8IoXH58vdJwlmD5k_BrYjBCFqtjU130_provenance.